<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160610</url>
  </required_header>
  <id_info>
    <org_study_id>ITEM</org_study_id>
    <nct_id>NCT05160610</nct_id>
  </id_info>
  <brief_title>Improving Thrombolysis Implementation Based on Electronic Monitoring in Acute Ischemic Stroke (ITEM)</brief_title>
  <official_title>Improving Thrombolysis Implementation Based on Electronic Monitoring in Acute Ischemic Stroke (ITEM): a Cluster Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A cluster randomized controlled trial will be conducted. Hospitals in Zhejiang Province,&#xD;
      China, will be randomized into two arms (1:1): an intervention arm and a control arm.&#xD;
&#xD;
      Hospitals in the intervention arm will receive a multilevel intervention based on the AACTT&#xD;
      theory, whereas hospitals in the control arm will receive no intervention and maintain&#xD;
      routine care. All the hospitals will receive electronic monitoring. Hospitals with no stroke&#xD;
      center or with &lt;20 cases received thrombolysis per year will be excluded from the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thrombolysis rate within 4.5 hours</measure>
    <time_frame>Up to 4.5 hours</time_frame>
    <description>The proportion of acute ischemic stroke patients within 4.5 hours of onset</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thrombolysis rate within 3 hours</measure>
    <time_frame>Up to 3 hours</time_frame>
    <description>The proportion of acute ischemic stroke patients within 3 hours of onset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Excellent neurological outcomes</measure>
    <time_frame>At 90 days</time_frame>
    <description>Score of 0 to 1 on the modified Rankin Scale, on which scores range from 0 (no neurologic deficit) to 6 (death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Favorable neurological outcomes</measure>
    <time_frame>At 90 days</time_frame>
    <description>Score of 0 to 1 on the modified Rankin Scale, on which scores range from 0 (no neurologic deficit) to 6 (death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Scale score</measure>
    <time_frame>At 90 days</time_frame>
    <description>The distribution of modified Rankin Scale score at 90 days, on which scores range from 0 (no neurologic deficit) to 6 (death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death rate</measure>
    <time_frame>At 90 days</time_frame>
    <description>All-cause death rate at 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic transformation</measure>
    <time_frame>At 7 days</time_frame>
    <description>the presence of hemorrhagic transformation is defined according to European Cooperative Acute Stroke Study (ECASS) II trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracranial hemorrhage</measure>
    <time_frame>At 7 days</time_frame>
    <description>Intracranial hemorrhage at 24 hours associated with an increase of ≥4 points of NIHSS score from baseline, according to European Cooperative Acute Stroke Study (ECASS) II trial</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Door-to-image time</measure>
    <time_frame>Up to 4.5 hours</time_frame>
    <description>The time between hospital arrival and the initiation of image</description>
  </secondary_outcome>
  <other_outcome>
    <measure>the proportion of acute ischemic stroke patients with Door-to-Needle Time≤60min</measure>
    <time_frame>Up to 4.5 hours</time_frame>
    <description>Difference between intervention arm and control arm in the percentage of patients receiving thrombolysis within 60 minutes of stroke onset</description>
  </other_outcome>
  <other_outcome>
    <measure>Door-to-needle time</measure>
    <time_frame>Up to 4.5 hours</time_frame>
    <description>The time between hospital arrival and the initiation of IVT</description>
  </other_outcome>
  <other_outcome>
    <measure>Onset-to-needle time</measure>
    <time_frame>Up to 24 hours</time_frame>
    <description>The time between the symptom onset and the initiation of IVT</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2720</enrollment>
  <condition>Thrombolysis Rate</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>receiving multilevel intervention, electronic monitoring and stroke registry participation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>receiving routine care , electronic monitoring and stroke registry participation</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Multilevel intervention</intervention_name>
    <description>Multilevel intervention based on AACTT theory</description>
    <arm_group_label>Intervention group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients presented with clinical signs of acute ischemic stroke within 4.5 hours of&#xD;
             stroke onset&#xD;
&#xD;
          2. Patient's age is &gt;18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Contraindication for intravenous thrombolysis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zexin Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ethics committee the second affiliated hospital, school of medicine, Zhejiang University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Lou, PhD</last_name>
    <phone>13958007213</phone>
    <email>loumingxc@vip.sina.com</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 16, 2021</study_first_submitted>
  <study_first_submitted_qc>December 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 6, 2021</last_update_submitted>
  <last_update_submitted_qc>December 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute ischemic stroke</keyword>
  <keyword>Electronic monitoring</keyword>
  <keyword>Intravenous thrombolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

